Coenzyme Q10 levels are low and may be associated with the inflammatory cascade in septic shock

[1]  M. Singer,et al.  Potential metabolic consequences of statins in sepsis* , 2011, Critical care medicine.

[2]  M. Donnino,et al.  Thiamine deficiency in critically ill patients with sepsis. , 2010, Journal of critical care.

[3]  K. Hedenmalm,et al.  Muscle toxicity with statins , 2010, Pharmacoepidemiology and drug safety.

[4]  Gian Paolo Littarru,et al.  Clinical aspects of coenzyme Q10: an update. , 2010, Nutrition.

[5]  J. Windsor,et al.  A systematic review of experimental treatments for mitochondrial dysfunction in sepsis and multiple organ dysfunction syndrome. , 2009, Free radical biology & medicine.

[6]  O. Huet,et al.  Alterations of mitochondrial function in sepsis and critical illness , 2009, Current opinion in anaesthesiology.

[7]  M. Kwak,et al.  Inhibitory effect of simvastatin on the TNF-α- and angiotensin II-induced monocyte adhesion to endothelial cells is mediated through the suppression of geranylgeranyl isoprenoid-dependent ROS generation , 2008, Archives of pharmacal research.

[8]  P. Sachdanandam,et al.  Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin. , 2007, Basic & clinical pharmacology & toxicology.

[9]  R. Rosenson,et al.  Statins and sepsis: multiple modifications at multiple levels. , 2007, The Lancet. Infectious diseases.

[10]  A. Pesce,et al.  Age-related changes in plasma coenzyme Q10 concentrations and redox state in apparently healthy children and adults. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[11]  S. Dimauro,et al.  Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. , 2004, Archives of neurology.

[12]  S. Ridley,et al.  Drugs in anaesthesia , 2003, Anaesthesia.

[13]  J. Verhoef,et al.  Lipoprotein metabolism in patients with severe sepsis , 2003, Critical care medicine.

[14]  John Land,et al.  Association between mitochondrial dysfunction and severity and outcome of septic shock , 2002, The Lancet.

[15]  M. Meisner,et al.  Markers of endothelial damage in organ dysfunction and sepsis , 2002, Critical care medicine.

[16]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[17]  F. Mach,et al.  Statins as a newly recognized type of immunomodulator , 2000, Nature Medicine.

[18]  G. Watts,et al.  Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. , 1993, Journal of clinical pathology.

[19]  R. Bone,et al.  Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome , 1993, Annals of Internal Medicine.

[20]  D. Remick,et al.  Effects of coenzyme Q10 on the mediator cascade of sepsis. , 1993, Circulatory shock.

[21]  J. Vincent,et al.  Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. , 1993, Chest.

[22]  P Franchimont,et al.  Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. , 1992, Annals of surgery.

[23]  L. G. Thijs,et al.  Increased plasma levels of interleukin-6 in sepsis [see comments] , 1989 .

[24]  C. Speil.  Statin Therapy Is Associated with Decreased Mortality in Patients with Infection , 2009 .

[25]  M. Fink.  Cytopathic hypoxia. Mitochondrial dysfunction as mechanism contributing to organ dysfunction in sepsis. , 2001, Critical care clinics.

[26]  G. Littarru,et al.  Distribution of antioxidants among blood components and lipoproteins: Significance of lipids/CoQ10 ratio as a possible marker of increased risk for atherosclerosis , 1999, BioFactors.

[27]  L A Aarden,et al.  Increased plasma levels of interleukin-6 in sepsis. , 1989, Blood.